IMPORTANCE OF THE AMIDE BOND OF THIORPHAN IN THE INHIBITOR-ENKEPHALINASE DOCKING PROCESS DEMONSTRATED WITH SOME THIORPHAN ISOSTERES.


Monteil Thierry, ^a Kotera Mitsuharu, ^a Duhamel Lucette, ^a Duhamel Pierre, ^a
Gros Claude, ^b Noël Nadine, ^b Schwartz Jean Charles, ^{b*} and Lecomte Jeanne Marie ^c.

^a URA 464 CNRS et IRCOF, BP 118, 76134 Mont Saint Aignan Cedex, France.
 ^b UA 109 INSERM, Centre Paul Broca, 2ter rue d'Alésia, 75014 Paris, France.
 ^c Laboratoire Bioprojet, 30 rue des Francs Bourgeois, 75003 Paris, France.

(Received 24 March 1992)

Abstract: Syntheses and biological activities of four thiorphan isosteres or analogs are described. The central amide linkage is replaced by ketomethylene, aminomethylene, thioamide, and trans-olefinic functionalities. Double chelation mechanism for the inhibitor-enkephalinase docking process is proposed.

The zinc-containing peptidase currently called enkephalinase, neutral endopeptidase or atriopeptidase (recommended names and numbers given by the Enzyme Commission: membrane metalloendopeptidase, EC 3.4.24.11) is responsible for the inactivation of endogenous enkephalins¹, a group of opioid pentapeptides and atrial natriuretic factor², a 28-aminoacid polypeptide hormone secreted by the heart. Therefore, inhibition of this peptidase results in therapeutically useful effects in the gastrointestinal, central nervous system and cardiovascular fields. Thiorphan 1 [(RS)-N-[1-oxo-2-(mercaptomethyl)-3-phenylpropyl] glycine] (fig. 1) the first of the enkephalinase inhibitors is also one of the most potent³. The importance of the zinc and arginine binding functions (SH, COOH) of thiorphan 1 is illustrated by the marked loss of *in vitro* potency in acetorphan 2 a compound in which they are both esterified (fig. 1), but which is used as a prodrug crossing biological barriers.



950 T. MONTEIL et al.

This work describes an investigation of the influence of various chemical modifications of the amide bond of thiorphan 1 in the inhibitor-enkephalinase docking process. Four different moieties have been used as amide group replacements (fig. 2): the ketomethylene group (-COCH₂-); the aminomethylene group (-CH₂NH-); the thioamide group (-CSNH-); and the *trans* olefinic group (-C=C-).

This paper presents the synthesis and the *in vitro* enkephalinase inhibitory data of these thiorphan isosteres or analogs.

Fig. 2

Ketomethylene analog 3 (scheme 1)⁴.

Acylation of ethyl *tert*-butyl 2-benzylmalonate by β -methoxycarbonylpropionyl chloride⁵ followed by decarboxylation and basic hydrolysis led to the diacid **7**. The Mannich reaction gave the methylene ketoacid **8**. The Michaël addition of thioacetic acid afforded the thioacetyl acid **9** which was hydrolysed enzymatically⁶ to the compound **3**.

Scheme 1 Reagents and conditions: i, a (EtO) $_2$ Mg, ClCO(CH $_2$)cCO $_2$ Me, Et $_2$ O reflux, 3 h, b CF $_3$ CO $_2$ H, 12 h (70%); ii, KOH, H $_2$ O, room temp., 12 h (86%); iii, Et $_2$ NH, HCHO 37 wt. % aq, room temp. 12 h (42%); iv, CH $_3$ COSH, 70°C, 12 h (53%); v, enzymatic hydrolysis.

Aminomethylene analog 4 (scheme 2)4.

The amidation of 2-(acetylthiomethyl)-3-phenyl propanoic acid⁷ by means of DCC and HOBT with ammonium chloride, followed by alkaline hydrolysis led to the mercapto amide 10. Reduction of this, using diborane furnished the 2-mercaptomethyl-3-phenyl propylamine hydrochloride 11. After oxidative dimerization in alkaline medium, N-alkylation with benzyl bromoacetate was carried out by using NEt(iPr)₂ as base. Hydrolysis of the ester function afforded the acid 13. Just before use, the disulfide was reduced with dithiothreitol (DTT) to afford the aminomethylene analog 4.

Scheme 2Reagents and conditions: i, NH₄Cl, NEt₃, DCC, HOBT, THF, CHCl₃, room temp., 6 h (56%); ii, NaOH, H₂O, MeOH, under argon, room temp., 2 h (75%); iii, $_{2}$ B₂H₆. THF reflux, under argon, 48 h, $_{2}$ 3N HCl, (95%); iv, $_{2}$ NaOH, H₂O, MeOH, room temp., $_{2}$ 3 days, (74%), $_{2}$ ($_{2}$ Prom temp.) BrCH₂CO₂CH₂Ph, THF, -20°C to room temp. over 0.5 h then room temp., $_{2}$ 12 h (34%); v, NaOH, H₂O, THF, room temp., $_{2}$ 12 h (78%); vi, dithiothrelitol.

Thioamide isostere 5 (sheme 3)4.

Acetorphan 2^7 was treated with Lawesson's reagent⁸ and gave thioamide 14 which was hydrolysed to the thioamide isostere 5 under argon.

952 T. MONTEIL et al.

Scheme 3 Reagents and conditions: i, Lawesson's reagent, toluene reflux, 6 h (80%); ii, NaOH, HO, MeOH, under argon, room temp. 3 h (75%).

trans-Carbon-carbon double bond isostere $\underline{6}$ (scheme 4)⁴.

The starting diol 15 was obtained through reduction of the diethyl benzylmalonate using LiAlH4 (73%). Mc Dougal's monosilylation followed by oxidation of the alcohol using pyridinium chlorochromate (PCC) gave the aldehyde 16. For the conversion of 16 into the β - γ unsaturated acid 18, we adapted the procedure of Hann et al. 10 in the synthesis of the isosteric Leu5-enkephalin analogue. Reaction between the Wittig ylide and the aldehyde 16 afforded the silylated trans-enyne 17. Treatment of the enyne with one equivalent of dicyclohexylborane followed by oxidation with alkalin hydrogen peroxide at 0°C led to the acid 18. Desilylation and esterification of 18 with HCl-MeOH afforded the trans olefinic ester 19. Mitsunobu type reaction 11 using thioacetic acid gives the acetylthio ester 20 which was hydrolysed enzymatically 6 to the required pure trans-carbon-carbon double bond isostere 6.

Scheme 4 Reagents and conditions: 1, NaH, THF, room temp, 0.75 h then tBu-Me₂SiCl, THF, room temp., 0.5 h (68%) ii, PCC, CH₂Cl₂, room temp., 2 h (61%); iii, Ph₃P+CH₂—C \equiv C-SiMe₃Bf, nBuLi, THF, 70°C 0.75 h then **16** THF, 70°C 0.5 h, and room temp. 0.5 h (59%); iv, a dicyclohexylborane, THF, 0°C, 1 h, b MeOH, 2N NaOH, H₂O₂0°C, 1 h (77.5%); v, HCl, MeOH reflux, 2 h (50%); vi, a Ph₃P, dethyl azodicarboxylate, THF, 0°C, 0.5 h, b CH₃COSH, then addition of **12** THF, 0°C 2 h then room temp. vii, enzymatic hydrolysis.

The compounds (3, 4, 5, 6) were evaluated as inhibitors of enkephalinase¹². Some preliminary biological results are reported in table 1. A number of conclusions may be drawn from these results.

Compounds	X - Y	Ki (nM)
Ketomethylene analog 3	-COCH ₂ -	64
Aminomethylene analog 4	-CH ₂ NH-	1000
Thioamide isostere 5	-CSNH-	275
Trans carbon-carbon double bond isostere 6	-C=C- (E)	1000
Thiorphan 1	-CONH-	2

Table 1. Inhibitory constants (Ki) of thiorphan and its isosteres or analogs

The thiorphan isosteres or analogs (3, 4, 5, 6) exhibit loss of potency in comparison with thiorphan 1, indicating that the modification of the amide function is not consistent with full biological activity.

The virtually identical activity of the ketomethylene analog 3 (Ki = 64 nM) with that of the N-methyl thiorphan (Ki = 57 nM)¹⁴ suggests that an intermolecular hydrogen bond, e. g. drug receptor interaction, from the amide hydrogen of thiorphan 1 is involved at the active site of the receptor.

However, the thioamide isostere 5 exhibits a poor activity although the NH acidity was increased. This observation supports a mechanism involving an hydrogen bonding interaction of the amide carbonyl of thiorphan 1: indeed, the sulfur atom of a thioamide is larger and has reduced hydrogen bonding capability 15, compared to the oxygen of an amide, factors that could decrease binding to the enzyme. Consistent with these results is the fact that the *trans*-carbon-carbon double bond isostere 6 (suppression of the amide group interactions) and the aminomethylene analog 4 (suppression of the amide carbonyl interaction and possible effect of charge, since the aminomethylene is likely to be protonated under assay conditions) poorly inhibits enkephalinase.

As a corollary to these observations it is clear that intermolecular hydrogen bonds, e. g. drug receptor interaction, from the two heteroatoms of the amide group of thiorphan 1 are involved at the active site of enkephalinase¹⁶.

The inhibitory activity of the ketomethylene analog 3 suggests that the hydrogen bond involving the amide carbonyl in thiorphan 1 is of primary importance in the inhibitor-ENK docking process. This result leads us to conclude that taking advantage of this interaction may constitute a new direction in the search of new enkephalinase inhibitors.

954 T. MONTEIL et al.

Acknowledgement: T. M. and N. N. thank Bioprojet for generous financial support.

References and Notes:

- Schwartz J. C., Malfroy B. and de la Baume S., Life Sci., 1981, 29, 1715. Schwartz J. C., Gros C., Lecomte J. M. and Bralet J., Life Sci., 1990, 47, 1279. Roques B. P., Fournie-Zaluski M. C., Soroca E., Lecomte J. M., Malfroy B., Llorens C., and 3 Schwartz J. C., Nature (London), 1980, 288, 286.
- All new compounds showed consistent spectral data, and gave satisfactory elemental analysis.
- 5 Kenner G. W., Rimmer J., Smith K. M., and Unsworth J. F., J. Chem. Soc., Perkin Trans 1,
- 6 Enzymatic hydrolysis. Mouse kidneys were homogenized with ultra turrax (Kinematica, Littau, Switzerland) for 1 min in 2 mL of ice-cold 50 mM Tris-HCl buffer, pH 7.4. The homogenate was centrifuged immediately for 20 min at 15,000 x g at 4°C. The pellet was resuspended in 70 mL of buffer, and the resulting suspension used as enzyme source. The particulate fraction (990 µL) was incubated at 37°C for 30 min in the presence of the protected inhibitors (10 µL, 10-2M).
- Roques B. P., Schwartz J. C., Lecomte J. M., Eur. Pat. Appl. EP 038,758, 28 Oct 1981.
- 8
- Scheibye S., Pedersen B. S., and Lawesson S. O., Bull. Soc. Chim. Belg., 1978, 87, 3. Mac Dougal P. G., Rico J. G., Oh Y. I., Condon B. D., J. Org. Chem., 1986, 51, 3388. Hann M. M., Sammes P. G., Kennewell P. D., and Taylor J. B., J. Chem. Soc., Perkin Trans 1, 10 1982, 307.
- Mitsunobu O., Synthesis, 1981, 1. 11
- Assay of Enkephalinase Activity. Mouse striatal membranes were used as the enzyme 12 source. Enkephalinase activity was evaluated with succinyl-Ala-Ala-Phe-amidomethylcoumarin as the substrate 13.
- Giros B., Gros C., Schwartz J. C., Danvy D., Plaquevent J. C., Duhamel L., Duhamel P., Vlaiculescu A., Costentin J. and Lecomte J. M., J. Pharmacol. Exp. Ther., 1987, 243, 666. 13
- 14 Fournie-Zaluski M. C., Lucas E., Waksman G., and Roques B. P., Eur. J. Biochem., 1984, 139, 267.
- La Cour T. F. M., Hansen H. A. S., Clausen K., Lawesson S. O., Int. J. Pept. Protein Res., 15 1983, 22, 509.
- The similar inhibitory activity of thiorphan 1 and retro-thiorphan are consistent with these 16 observations.
 - Roques B. P., Soroca E., Chaillet P., Costentin J., and Fournie-Zaluski M. C., Proc. Natl. Acad. Sci. USA, 1983, 80, 3178.